Observational Study of Finerenone Treatment Effects on Kidney Disease Progression in Adults with Type 2 Diabetes and Chronic Kidney Disease in Spain

What this Trial Is About

Researchers are conducting a prospective observational study to collect and analyze data from adults with chronic kidney disease CKD linked to type 2 diabetes T2D who are receiving the drug finerenone. CKD is a common complication in people with T2D that can worsen over time, potentially leading to kidney failure and heart problems. The study focuses on assessing changes in a risk score called the Klinrisk model, which estimates the progression of kidney disease based on routine lab tests. Participants are adults newly prescribed finerenone as part of their routine clinical care. Data collection spans up to 24 months per participant, with visits scheduled at inclusion, and follow-ups at approximately 6, 12, 18, and 24 months. The study will gather information on clinical characteristics, kidney function tests such as estimated glomerular filtration rate eGFR and urine albumin-to-creatinine ratio UACR, blood markers including glucose, hemoglobin, and potassium levels, and adverse events. During the study, participants will have data collected during five visits aligned with their usual care appointments. Researchers will monitor changes in the Klinrisk score after 12 and 24 months of finerenone treatment, track kidney and cardiovascular events, and record any adverse events. The study aims to understand how finerenone treatment relates to kidney disease progression in real-world practice over a two-year period.

An Observational Study, Called FINEXPLORER, to Learn More About How Well Finerenone Works in Adults in Spain With Chronic Kidney Disease (CKD) Linked to Type 2 Diabetes, by Looking at Changes in a CKD Risk Score